ClinicalTrials.gg
RecruitingNCT06446271Updated Jul 3, 2024

Biomarkers in SCOTland CardiomyopatHy Registry (Bio-SCOTCH)

An observational study in Cardiomyopathies, Genetic Predisposition and Cardiomyopathy, Primary, sponsored by NHS Greater Glasgow and Clyde. Recruiting at 1 site in United Kingdom. Open to participants aged 10 Years and older. Per ClinicalTrials.gov, last updated 2024-07-03.

Sponsored by NHS Greater Glasgow and Clyde · Observational

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
750
Ages
10 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies in Cardiomyopathies with a site in United Kingdom — 19 open to participants now, 24 under way, 5 of them phase 3. Cardiomyopathies · United Kingdom.

Planned enrollment
10th of 25
750 · median 267
Started
2024
with 2 others
Observational
25 of 51
10 open now
Primary completion
2027-03
later than 8 of 23 live
Registered
43rd of 51
by date
Lead sponsor
2 of 51
NHS Greater Glasgow and Clyde

Among the 51 studies in Cardiomyopathies with a site in United Kingdom, this one is the 10th largest by planned enrollment of the 25 observational ones that give a count, is one of 3 that started in 2024, is one of 25 observational ones, reaches primary completion later than 8 of the 23 other live ones, and was the 43rd registered.

Cardiomyopathies

556 studies on the registry are indexed under Cardiomyopathies; 153 are open to participants now.

Browse Cardiomyopathies studies →

Open to participants now

19 of the 51 studies in Cardiomyopathies with a site in United Kingdom are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 116 Cardiomyopathies studies recruiting now, 70 (60%) set no upper age limit and 18 (16%) stop at 75 or younger; 35 take children under 18; 22 take healthy volunteers.

This study: 10 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Cardiomyopathies with a site in United Kingdom, or all of them as a file.
02

Study summary

Genetic cardiomyopathy is increasingly recognised and can lead to heart failure, arrhythmia and sudden cardiac death. Some gene positive patients have rapidly progressive disease with high rates of heart failure and cardiac transplantation, while others present with SCD. Other gene positive patients will never develop cardiomyopathy. At present, we cannot distinguish between these groups and rely on expensive and labour-intensive surveillance by electrocardiography, echocardiography and sometimes cardiac magnetic resonance imaging.

This study will investigate existing and novel biomarkers (including blood, urine electrocardiographic and imaging) at various stages of disease in patients with a personal or family history of TTN, MYBPC3, LMNA, FLNC or DSP gene variant, which are known to cause cardiomyopathy.

Read the detailed description

There is a growing appreciation for the role that genetics play in the development of cardiomyopathy, which can lead to heart failure, arrhythmia and sudden cardiac death.

Increased use of genetic testing has identified numerous gene variants, which cause cardiomyopathy with dilated, hypertrophic, restrictive, non-dilated left ventricular and arrhythmogenic right ventricular phenotypes described.

Some gene variants cause a rapidly progressive cardiomyopathy with high rates of heart failure and cardiac transplantation, while others present with SCD, meaning that genotype-specific risk stratification and clinical surveillance is urgently needed. Some gene-positive individuals will never develop cardiomyopathy due to variable penetrance. At present, we cannot distinguish between these patients and therefore rely on expensive and labour-intensive surveillance by electrocardiography, echocardiography and sometimes cardiac magnetic resonance imaging. For every gene-positive affected individual with cardiomyopathy, cascade genetic testing will identify other gene-positive family members who are often asymptomatic and may not yet be affected.

A blood or urine-based biomarker that identifies pre-clinical disease or cardiomyopathy would allow for more efficient monitoring of gene positive people and could replace multiple, repeated electrocardiograms, echocardiograms and cardiac magnetic resonance imaging scans. A biomarker that accurately identifies pre-clinical cardiomyopathy could enable targeted early treatment. A biomarker that predicts future disease progression would be of high clinical value.

03

Conditions studied

  • Cardiomyopathies
  • Genetic Predisposition
  • Cardiomyopathy, Primary

Keywords

  • Cardiomyopathy
  • Genetic
  • Biomarkers
04

Who can participate

Ages eligible
10 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

People with a personal or family history of TTN, LMNA, MYBPC3, DSP, or FLNC gene variant who have been referred to the West of Scotland Inherited Cardiac Conditions Service clinic.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female ≥10 years of age
  • Written / assent
  • Pathogenic or likely pathogenic variant in a cardiomyopathy gene (TTN, LMNA, MYBPC3, DSP, FLNC) or undergoing predictive genetic testing (if negative these people would be invited to enter the control arm)

Exclusion criteria

Exclusion Criteria:

  • Unable to consent.
  • Geographical / social reasons preventing attending study centre
  • Unable to complete study assessments.
  • Severe non-cardiac disease expected to reduce \< 5 years
  • Current participation in a blinded drug interventional trial (or treatment within 4 weeks)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
750 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Gene positive participants (personal history of TTN, MYBPC3, LMNA, FLNC or DSP gene variant)

    Pathogenic and likely pathogenic variants defined by American College of Medical Genetics guidelines. Expected recruitment of: 300 TTN, 300 MYBPC3, up to 50 LMNA, up to 50 FLNC and up to 50 DSP

    Diagnostic Test: Plasma biomarker levels

  • Gene negative controls (family history of TTN, MYBPC3, LMNA, FLNC or DSP gene variant)

    Expected recruitment of 50 patients.

    Diagnostic Test: Plasma biomarker levels

Interventions

  • Diagnostic testPlasma biomarker levels

    This study will investigate existing and novel biomarkers (including blood, urine electrocardiographic and imaging) at various stages of disease in patients with a personal or family history of TTN, MYBPC3, LMNA, FLNC or DSP gene variant, which are known to cause cardiomyopathy. Cardiomyopathy will be defined per European Society of Cardiology cardiomyopathy guidelines and heart failure stage will be defined per American Heart Associate guidelines.

    Also known as: Electrocardiogram, Echocardiogram, Cardiac magnetic resonance imaging, 24-hour Holter monitor, Questionnaires (Kansas City Cardiomyopathy Questionnaire & General Practice Physical Activity Questionnaire), Urine biomarker levels

06

What researchers measure

Primary outcomes

  1. Biomarker performance

    Diagnostic performance of existing and novel biomarkers across the spectrum of disease in patients with pathogenic/ likely pathogenic TTN, MYBPC3, LMNA, FLNC or DSP gene variants.

    Time frame: 3 years

Secondary outcomes

  1. Biomarker correlation

    Correlation of biomarkers with cardiac imaging measures of inflammation and myocardial fibrosis in genetic cardiomyopathies.

    Time frame: 3 years

  2. Prediction of cardiomyopathy development

    Investigation of biomarkers that can predict which patients (who are gene positive without cardiomyopathy) will develop cardiomyopathy, heart failure, arrhythmia, or die

    Time frame: 3 years with long-term data linkage

  3. Prediction of cardiomyopathy progression

    Investigation of biomarkers that can predict which patients (who are gene positive with cardiomyopathy) will have progressive cardiomyopathy, heart failure, arrhythmia, or die.

    Time frame: 3 years with long-term data linkage

  4. Natural history of genetic cardiomyopathies

    Investigate the natural history of genetic cardiomyopathy due to variants in TTN, MYBPC3, LMNA, FLNC and DSP genes.

    Time frame: 3 years with long-term data linkage

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Mar 2027, 32 months after the start.

Of 119 non-industry observational studies under Cardiomyopathies, half reached primary completion within 87 months of starting (the median), counting those still running; a quarter within 34. This study's planned 32 months is below that.

Counting every sponsor, half of 141 studies reached it within 83 months; a quarter within 34.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2024
First posted
Jun 6, 2024
StartActual
Jun 26, 2024
Primary completionEst.
Mar 19, 2027
CompletionEst.
Mar 19, 2027
Last update
Jul 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06446271
Responsible party
Sponsor
First posted
Jun 6, 2024
Start date
Jun 26, 2024
Primary completion
Mar 19, 2027 (estimated)
Completion
Mar 19, 2027 (estimated)
Last update
Jul 3, 2024

Study contacts

Caroline J Coats, MBBS, PhD
Contact
Caroline.Coats@glasgow.ac.uk
0141 451 6121
Rachel C Myles, MBBS, PhD
Contact
Rachel.Myles@glasgow.ac.uk
0141 451 6121

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion